Briumvi 150 mg/6 mL (25 mg/mL) injection Images
Generic Name: ublituximab
This medication has been identified as Briumvi 150 mg/6 mL (25 mg/mL) injection. It is supplied by TG Therapeutics, Inc.
Briumvi is used in the treatment of Multiple Sclerosis and belongs to the drug class CD20 monoclonal antibodies. Briumvi 150 mg/6 mL (25 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Briumvi
- Generic Name
- ublituximab
- Strength
- 150 mg/6 mL (25 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- CD20 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- TG Therapeutics, Inc.
- National Drug Code (NDC)
- 73150-0150
More about Briumvi (ublituximab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
